PMID- 35327744
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220329
IS  - 2227-9067 (Print)
IS  - 2227-9067 (Electronic)
IS  - 2227-9067 (Linking)
VI  - 9
IP  - 3
DP  - 2022 Mar 7
TI  - Prospective Study on Prophylactic Micafungin Sodium against Invasive Fungal 
      Disease during Neutropenia in Pediatric & Adolescent Patients Undergoing 
      Autologous Hematopoietic Stem Cell Transplantation.
LID - 10.3390/children9030372 [doi]
LID - 372
AB  - BACKGROUND: Invasive fungal diseases (IFDs) increase the mortality rate of 
      patients with neutropenia who receive chemotherapy or have previously undergone 
      hematopoietic stem cell transplantation (HSCT). Micafungin is a broad-spectrum 
      echinocandin with minimal toxicity and low drug interactions. We therefore 
      investigated the efficacy and safety of prophylactic micafungin in pediatric and 
      adolescent patients who underwent autologous HSCT. METHODS: This was a phase II, 
      prospective, single-center, open-label, and single-arm study. From November 2011 
      to February 2017, 125 patients were screened from Seoul National University 
      Children's Hospital, Korea, and 112 were enrolled. Micafungin was administered 
      intravenously at a dose of 1 mg/kg/day (maximum 50 mg/day) from day 8 of 
      autologous HSCT until neutrophil engraftment. Treatment success was defined as 
      the absence of proven, probable, or possible IFD up to 4 weeks after therapy. 
      RESULTS: The study protocol was achieved without premature interruption in 110 
      patients (98.2%). The reasons interrupting micafungin treatment included early 
      death (n = 1) and patient refusal (n = 1). Treatment success was achieved in 109 
      patients (99.1%). Only one patient was diagnosed with probable IFD. No patients 
      were diagnosed with possible or proven IFD. In the full analysis set, 21 patients 
      (18.8%) experienced 22 adverse events (AEs); however, all AEs were classified as 
      "unlikely" related to micafungin. No patient experienced grade IV AEs nor 
      discontinued treatment, and none of the deaths were related to micafungin. 
      CONCLUSIONS: Our study demonstrated that micafungin is a safe and effective 
      option for antifungal prophylaxis in pediatric patients who underwent autologous 
      HSCT, with promising efficacy without significant AEs.
FAU - Kim, Bo-Kyung
AU  - Kim BK
AD  - Department of Pediatrics, College of Medicine, Seoul National University, Seoul 
      03080, Korea.
AD  - Cancer Research Institute, Seoul National University, Seoul 03080, Korea.
AD  - Wide River Institute of Immunology, Hongcheon 25159, Korea.
FAU - Choi, Jung-Yoon
AU  - Choi JY
AD  - Department of Pediatrics, College of Medicine, Seoul National University, Seoul 
      03080, Korea.
AD  - Cancer Research Institute, Seoul National University, Seoul 03080, Korea.
AD  - Wide River Institute of Immunology, Hongcheon 25159, Korea.
FAU - Hong, Kyung-Taek
AU  - Hong KT
AUID- ORCID: 0000-0002-8822-1988
AD  - Department of Pediatrics, College of Medicine, Seoul National University, Seoul 
      03080, Korea.
AD  - Cancer Research Institute, Seoul National University, Seoul 03080, Korea.
AD  - Wide River Institute of Immunology, Hongcheon 25159, Korea.
FAU - An, Hong-Yul
AU  - An HY
AD  - Department of Pediatrics, College of Medicine, Seoul National University, Seoul 
      03080, Korea.
AD  - Cancer Research Institute, Seoul National University, Seoul 03080, Korea.
AD  - Wide River Institute of Immunology, Hongcheon 25159, Korea.
FAU - Shin, Hee-Young
AU  - Shin HY
AD  - Department of Pediatrics, College of Medicine, Seoul National University, Seoul 
      03080, Korea.
AD  - Cancer Research Institute, Seoul National University, Seoul 03080, Korea.
AD  - Wide River Institute of Immunology, Hongcheon 25159, Korea.
FAU - Kang, Hyoung-Jin
AU  - Kang HJ
AD  - Department of Pediatrics, College of Medicine, Seoul National University, Seoul 
      03080, Korea.
AD  - Cancer Research Institute, Seoul National University, Seoul 03080, Korea.
AD  - Wide River Institute of Immunology, Hongcheon 25159, Korea.
LA  - eng
GR  - AKR-MYC-2011-03/Astellas Pharma (South Korea)/
PT  - Journal Article
DEP - 20220307
PL  - Switzerland
TA  - Children (Basel)
JT  - Children (Basel, Switzerland)
JID - 101648936
PMC - PMC8947337
OTO - NOTNLM
OT  - adolescent
OT  - autologous hematopoietic stem cell transplantation
OT  - invasive fungal disease
OT  - micafungin
OT  - pediatric
COIS- The authors declare no conflict of interest.
EDAT- 2022/03/26 06:00
MHDA- 2022/03/26 06:01
PMCR- 2022/03/07
CRDT- 2022/03/25 01:05
PHST- 2021/12/23 00:00 [received]
PHST- 2022/02/18 00:00 [revised]
PHST- 2022/02/28 00:00 [accepted]
PHST- 2022/03/25 01:05 [entrez]
PHST- 2022/03/26 06:00 [pubmed]
PHST- 2022/03/26 06:01 [medline]
PHST- 2022/03/07 00:00 [pmc-release]
AID - children9030372 [pii]
AID - children-09-00372 [pii]
AID - 10.3390/children9030372 [doi]
PST - epublish
SO  - Children (Basel). 2022 Mar 7;9(3):372. doi: 10.3390/children9030372.